Search

everythinglearnresearchcommunity

for

Search:↓

The individual reversed their hair loss using oral dutasteride and topical minoxidil, and experienced side effects including low libido, tiredness, and brain fog. They started treatment at age 26 and have a high-protein diet and exercise regularly.

Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).

PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.

PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.

A 26-year-old is experiencing hair thinning and has received conflicting diagnoses of androgenetic alopecia and telogen effluvium. They are considering treatments like dutasteride, oral and topical minoxidil, and are unsure whether to start treatment or pursue further diagnosis like a scalp biopsy.

The conversation is about using finasteride and KX826 for hair loss treatment. The original poster is using 0.25 mg of finasteride every other day due to side effects at a higher dose.

DHT is not the only cause of male pattern hair loss; genetic sensitivity, inflammation, and fibrosis also contribute. GHK-Cu, a copper peptide, is being explored as an alternative treatment to finasteride and minoxidil, showing potential in improving follicle health.

Dutasteride significantly improved hair health and reduced shedding for a woman with PCOS and hyperandrogenism, without causing depression or anxiety, unlike finasteride. Dutasteride also helped with PMDD symptoms and had no side effects, though it changed hair texture.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

User seeks KX-826 anti-androgen product and asks for purchase suggestions and experiences. Dave-8D recommends buying powder from the same website and making a topical solution, mentioning possible high dosage from Minoxidil max causing side effects.

ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.

The conversation discusses androgenic alopecia (AGA) and its treatments, focusing on finasteride, minoxidil, and ketoconazole shampoo. Finasteride is recommended as essential for preventing further hair loss.

The user is using a combination of hair loss treatments including dutasteride, minoxidil, RU58841, low-level laser therapy, ketokonozole, supplements, Viviscal, Nutrafol, microneedling, PRP, and scalp Botox injections, but is still experiencing hair shedding and thinning. Despite being on this regimen for two years, the user's hair condition is worsening, and they are seeking advice on what else they can do.

Stemoxydine's effects on hair growth are uncertain and not well-studied, with users reporting mixed results and concerns about maintaining gains. Some users combine it with 5AR inhibitors like Dutasteride, but results vary, and conditions like lichen planopilaris complicate treatment.

A 21-year-old male with a thyroid condition noticed his hair thinning uniformly without a receding hairline. He is considering using a 5ARI to prevent further baldness if he starts TRT.

A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.

A young female diagnosed with Lichen planopilaris (LPP) experienced years of misdiagnosis and ineffective treatments, including a hair transplant and other procedures. She is considering litigation due to the misdiagnosis and has learned that LPP is chronic, hair loss can be stopped with ongoing medication, but lost hair cannot regrow.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.

The user experienced significant hair loss after 9 months of using 0.5mg dutasteride and oral minoxidil, possibly due to alopecia areata. It is advised to consult a doctor for accurate diagnosis and treatment, as dutasteride and finasteride may not be effective.

RU58841 was ineffective for OP, who is considering adding KX-826 with finasteride. User8 suggests KX-826 may help when combined with minoxidil and dutasteride.

GHK-Cu is discussed for its potential anti-aging and healing properties, with some users considering its effects on hair growth. One user mentions using Folligen Spray and topical finasteride, noting improved healing but uncertain hair growth results.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

The user has been using finasteride for hair loss and is considering adding RU58841. They ask about RU58841's effectiveness, potential heart side effects, duration of action, dosage increase over time, transitioning to GT20029, and where to find the liquid form.

Minoxidil, finasteride, and RU58841 are discussed as treatments for androgenetic alopecia (AGA). The conversation questions their effectiveness and whether they are scams.

The user must stop minoxidil due to a heart murmur and is considering alternatives like nanoxidil or stemoxydine while continuing dutasteride. Suggestions include adding pyrilutamide and alfatradiol or switching to topical minoxidil at a lower concentration.